A new film about leukemia drugs opened in Chinese theaters last week, and it’s already become a blockbuster hit. The movie, called “Dying to Survive,” brought in $232 million in its first five days, a pace that gives it a chance to become China’s biggest-ever box-office success.

The dark comedy centers around a Chinese man who illegally smuggles cheap generic leukemia drugs from India to sell to Chinese patients who can’t afford the medication available through official channels — a pricey drug called Glinic sold by a greedy Swiss pharma company. Sound familiar?

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Comments are closed.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy